What's going on with AERI?
Aerie Pharmaceuticals (AERI) has announced that its' Board of Directors has appointed a new Interim Executive Chairman of the Board of Directors of the Company, Benjamin F. McGraw, III, Pharm.D. This news comes after the previous Chairman and CEO, Vicente Anido, PhD. stepped down from his roles. Aerie Pharmaceuticals hopes to appoint a new Chief Executive Officer as well, as the company intends to separate the roles of Chairman and Chief Executive Officer now.
Vicente Anido shares his appreciation for the company stating, "It’s been an exciting experience making Dr. David Epstein’s dream of developing a unique glaucoma product that treats the underlying causes of the disease a reality. Many thanks to the Aerie team for the great memories.”
What does this mean for AERI?
Speaking on the future, Benjamin F. McGraw states, "On behalf of the Board, I would like to express our sincere appreciation to Vince for all his contributions over the years since Aerie was a private company through the public offering and into Aerie becoming a commercial stage company. Under his leadership, Aerie now has two clearly differentiated products on the market and we believe we have a very good portfolio of products in development. We believe the succession plan we have in place will serve the shareholders well. We have a strong board of directors and each one of them has committed to helping the Company during this transition.”
AERI has an Overall Score of 50. Find out what this means to you and get the rest of the rankings on AERI!
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.
